DENVER, Colo., 23 July, 2024 (247marketnews.com) – (Nasdaq:ADIL) are discussed in this article.
Adial Pharmaceuticals, Inc. (ADIL) is experiencing a surge in pre-market trading, with a price of $1.605 indicating a substantial increase from the previous close of $1.06. The heightened trading volume of 14.9 million shares reflects a growing market interest, with a notable percentage change of 73.68% since the market opening. Investors are drawn to ADIL’s positive momentum, as technical analysis points towards a potential uptrend continuation, presenting an enticing opportunity for growth-focused investors.
In parallel, Adial Pharmaceuticals has achieved a pivotal advancement in its development of AD04, a cutting-edge treatment for Alcohol Use Disorder (AUD). Following the successful completion of the initial study cohort, the Company has progressed to the second cohort in the pharmacokinetics phase. AD04, a genetically targeted serotonin-3 receptor antagonist, holds significant promise in treating AUD among heavy drinking patients.
The ongoing study, which includes individuals with moderate alcohol consumption, is a strategic step towards addressing the critical issue of AUD with a tailored therapeutic approach. The forthcoming release of results from both study cohorts in the fourth quarter of 2024 is eagerly awaited, as it will offer crucial insights into the efficacy and safety profile of AD04.
Adial Pharmaceuticals’ advancement in the development of AD04 underscores its dedication to pioneering treatments for addiction and related disorders. The Company’s proactive approach to addressing unmet medical needs and enhancing patient care reaffirms its position as a leader in the biopharmaceutical landscape. Stay informed about Adial Pharmaceuticals’ groundbreaking research in addiction therapy by visiting the official company website.
For further information, please contact:
[Company Name]
[Contact Information]
— End of Press Release —
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com